Research-Peptide Enforcement in 2024: Dated Record

Updated August 23, 2026

Paradigm Peptides' storefront went offline in March 2024, the first event in this index's enforcement record. FDA reviewed the Xcel Research website in October, issued warning letters to four research-peptide sellers on December 10 — Summit Research Peptides, Prime Peptides, Xcel Research, SwissChems — and noticed the batch in its December 17 Roundup.

The year in dates

March: Paradigm Peptides goes offline

The year opens with a storefront disappearing, not an agency action. Paradigm Peptides' website stopped operating in March 2024, twenty-one months before any plea in the federal case that eventually attached to the company. Within 2024 itself there was only the dark site; the pleas of December 2025 and the sentencing of July 2026 belong to later pages of this record. The full matter, including the lookalike domain that surfaced afterward claiming no affiliation, is documented at the Paradigm Peptides case record.

October: the Xcel Research site review

The warning letter FDA later sent to Xcel Research LLC states that the agency reviewed xcelpeptides.com in October 2024. The review found product listings under seven names: "RETA," "CagriLean," "CAGRILINTIDE," "MAZDUTIDE," "SEMA," "SURVODUTIDE," and "SERMORELIN." Two months separate that review from the letter's December 10 date — the earliest documented instance in this record of the agency reading a research-peptide storefront before acting on it.

December 10: four letters on one date

All four recipients sold GLP-1-class compounds and labeled them for research use only. In each letter, the agency set that labeling against material the seller itself had published: product listings in all four cases, and for Summit Research Peptides, a post on the company's own Facebook account carrying a therapeutic-outcome claim for a two-compound pairing from its catalog. Each recipient was given 15 working days to respond in writing. What any recipient did after receiving its letter is not part of this index's verified record. Per-entity findings and letter numbers are collected in the December 2024 batch record.

December 17: the Roundup notice

A week after issuance, FDA's Roundup of December 17, 2024 gave the batch public notice beyond the warning-letters database itself — the agency's own secondary announcement, and the last dated event of the year.

Where 2024 sits in the sequence

This is the first of three year pages. 2024 contributed one vendor exit and one four-letter batch; the years that followed added a facility raid, a voluntary closure, pleas, a seven-letter batch, and sentencing. The full multi-year table is the enforcement chronology, and every entity named on this page has an entry in the vendor index.

Sources

1. FDA Warning Letter, Summit Research Peptides, 695607-12102024. fda.gov
2. FDA Warning Letter, Prime Vitality Inc dba Prime Peptides, 695156-12102024. fda.gov
3. FDA Warning Letter, Xcel Research LLC, 694608-12102024. fda.gov
4. FDA Warning Letters index (retrieves the SwissChems letter by recipient name). fda.gov
5. FDA Roundup, December 17, 2024. fda.gov
6. CBS News coverage of the Paradigm Peptides case. cbsnews.com

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.